Aspergillus fumigatus during stable state and exacerbations of COPD

European Respiratory Journal

Volumn 43, Issue 1, 2014, Pages 64-71

  Bafadhel, Mona ^a   McKenna, Susan ^b   Agbetile, Joshua ^b   Fairs, Abbie ^b   Desai, Dhananjay ^b   Mistry, Vijay ^b   Morley, Joseph P ^b   Pancholi, Mitesh ^b   Pavord, Ian D ^a   Wardlaw, Andrew J ^b   Pashley, Catherine H ^b   Brightling, Christopher E ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CORTICOSTEROID; IMMUNOGLOBULIN E;

ADULT; AGED; ASPERGILLUS FUMIGATUS; ATOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; FUNGAL COLONIZATION; FUNGUS CULTURE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SENSITIZATION; SMOKING; SPUTUM ANALYSIS; VERY ELDERLY;

ADULT; AGED; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 84891951643     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00162912     Document Type: Review

References (33)

1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006; 27: 397-412.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
3. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
4. Jeffery PK. Structural and inflammatory changes in COPD: A comparison with asthma. Thorax 1998; 53: 129-136.
5. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
6. O'Donnell R, Breen D, Wilson S, et al. Inflammatory cells in the airways in COPD. Thorax 2006; 61: 448-454.
7. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30: 782-800.
8. Al-Alawi A, Ryan CF, Flint JD, et al. Aspergillus-related lung disease. Can Respir J 2005; 12: 377-387.
9. Wardlaw A, Geddes DM. Allergic bronchopulmonary aspergillosis: A review. J R Soc Med 1992; 85: 747-751.
10. Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005; 60: 1004-1013.
11. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1984; 74: 645-653.
12. Greenberger PA, Miller TP, Roberts M, et al. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy 1993; 70: 333-338.
13. Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7: Suppl. 2, 25-31.
14. Agarwal R, Hazarika B, Gupta D, et al. Aspergillus hypersensitivity in patients with chronic obstructive pulmonary disease: COPD as a risk factor for ABPA Med Mycol 2010; 48: 988-994.
15. Fairs A, Agbetile J, Hargadon B, et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182: 1362-1368.
16. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
17. Brusasco V, Crapo R, Viegi G. Coming together: The ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J 2005; 26: 1-2.
18. Health Protection Agency. Investigation of bronchoalveolar lavage, sputum and associated specimens. National Standard Method BSOP 57 Issue 2.3.
19. Pashley CH, Fairs A, Morley JP, et al. Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Med Mycol 2012; 50: 433-438.
20. Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: Reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154: 308-317.
21. Pizzichini MM, Popov TA, Efthimiadis A, et al. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 866-869.
22. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
23. Guyatt G. Measuring health status in chronic airflow limitation. Eur Respir J 1988; 1: 560-564.
24. Brightling CE, Monterio W, Green RH, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: Safety and repeatability. Respir Med 2001; 95: 999-1002.
25. Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; 3: CD001108.
26. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179: 11-18.
27. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342: 756-762.
28. Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: An emerging fungal pathogen. Clin Microbiol Infect 2005; 11: 427-429.
29. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997; 111: 732-743.
30. Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10: R31.
31. Lucena P, Barberán J, Eroles G, et al. Significance of lower respiratory tract cultures yielding Aspergillus spp. growth in a hospital without transplant patients. Rev Esp Quimioter 2010; 23: 190-195.
32. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010; 5: E8578.
33. Wargo MJ, Hogan DA. Fungal-bacterial interactions: A mixed bag of mingling microbes. Curr Opin Microbiol 2006; 9: 359-364.